BACIL PHARMA LTD.
BACPHAR (BSE 524516) · ISIN INE711D01018 · Pharmaceuticals · Est. 1987 · listed 1994 · website
Not on any surveillance list
In Q2 FY27 (quarter to 30 September 2026, consolidated), revenue was ₹0 cr and profit after tax ₹0.09 cr.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q2 FY27 consolidated | ₹0 cr | ₹0.09 cr | 0.00 | 14 Oct 2026 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 30 Sep 2026 standalone | ₹25.27 cr | ₹0 cr | ₹25.34 cr |
| 31 Mar 2026 standalone | ₹24.81 cr | ₹0 cr | ₹27.39 cr |
| 30 Sep 2025 standalone | ₹26.35 cr | ₹0 cr | ₹26.59 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 0.00% | — | — | 100.00% |
Latest filings
- Un-Audited Financial Results for the Quarter and Half Yearly Ended 30th September, 2026 14 October 2026 · BSE
- Outcome of Board Meeting held on 14th October, 2026 14 October 2026 · BSE
- Scrutinizers Report for the Annual General Meeting of the Company for FY 2025-2026 24 September 2026 · BSE
- Outcome/Proceeding of Annual General Meeting of the Company 23 September 2026 · BSE
- Annual Report FY2025-26 (New) 31 August 2026 · BSE
Other companies in Pharmaceuticals
- Sun Pharmaceutical Industries Limited
- Lupin Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Mankind Pharma Limited
- Aurobindo Pharma Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.